Table 3.

Summary of univariable Cox regression analyses of expression levels of candidate genes in breast carcinomas associated with overall survival (OS) without regard to ER or PR status

Gene symbol	β	HR	95% CI (HR)	p value	Adjusted p value
Methylxanthine alkaloid receptors
ADORA1	0.14	1.15	(0.97, 1.36)	0.097	0.334
ADORA2A	− 0.08	0.93	(0.76, 1.13)	0.457	0.790
ADORA2B	0.12	1.13	(0.98, 1.30)	0.087	0.334
ADORA3	0.05	1.06	(0.85, 1.31)	0.623	0.790
DRD2	0.11	1.11	(0.93, 1.33)	0.252	0.604
CACNA1S	0.15	1.16	(0.84, 1.60)	0.366	0.790
RYR1	− 0.05	0.95	(0.73, 1.23)	0.699	0.790
SPECC1L	− 0.10	0.90	(0.61, 1.33)	0.606	0.790
Phosphodiesterases
PDE1A	0.16	1.17	(0.99, 1.38)	0.074	0.334
PDE1B	0.32	1.38	(0.97, 1.96)	0.072	0.334
PDE1C	0.16	1.17	(0.58, 2.36)	0.657	0.790
PDE3A	0.42	1.52	(0.34, 6.84)	0.584	0.790
PDE4A	− 0.34	0.72	(0.59, 0.86)	0.001	0.010
PDE4B	− 0.02	0.98	(0.85, 1.12)	0.724	0.790
PDE5A	− 0.05	0.95	(0.65, 1.39)	0.804	0.839
Enzymes metabolizing methylxanthines
CYP1A2	− 0.02	0.98	(0.33, 2.89)	0.965	0.965
CYP2A6	− 0.17	0.84	(0.70, 1.01)	0.069	0.334
CYP3A4	− 0.11	0.90	(0.62, 1.29)	0.554	0.790
CYP2C8	− 0.11	0.89	(0.76, 1.06)	0.187	0.499
CYP2C9	0.10	1.10	(0.80, 1.52)	0.558	0.790
CYP2E	− 0.29	0.75	(0.61, 0.93)	0.008	0.095
NAT2	− 0.03	0.97	(0.84, 1.13)	0.712	0.790
XDH	− 0.05	0.95	(0.80, 1.13)	0.562	0.790

Genes with expression levels that were significant at a discovery cutoff and adjusted p-value < 0.30 are shown in bold